Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

Hadoux, J; Elisei, R; Brose, MS; Hoff, AO; Robinson, BG; Gao, M; Jarzab, B; Isaev, P; Kopeckova, K; Wadsley, J; Führer, D; Keam, B; Bardet, S; Sherman, EJ; Tahara, M; Hu, MI; Singh, R; Lin, Y; Soldatenkova, ; Wright, J; Lin, B; Maeda, P; Capdevila, J; Wirth, LJ

Wirth, LJ (通讯作者)，Massachusetts Gen Hosp, Canc Ctr, 55 Fruit St, Boston, MA 02114 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2023; 389 (20): 1851

Abstract

Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer in a phase 1-2 ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索